Spinal cord 41:369378 Hayakawa K, Okazaki R, Morioka K, Nakamura K, Tanaka S, Ogata T (2014) Lipopolysaccharide preconditioning facilitates M2 activation of resident microglia after spinal cord injury
BPC157 Common Side Effects: Mild injection site irritation (redness, swelling, itchiness) Headaches (rare, usually from high doses) Nausea when taken orally (especially on an empty stomach) Risk Profile: Very low toxicity No hormonal suppression No effect on liver enzymes or cholesterol Safe to use during PCT or while recovering from injury BPC157 appears to have a strong safety margin with no known systemic toxicity in animal models. Sikiric et al., Current Pharmaceutical Design MK677 (Ibutamoren) Common Side Effects: Increased appetite (sometimes extreme) Water retention and mild bloating Fatigue or lethargy in some users Numbness or tingling (carpal tunnellike symptoms) Mild insulin resistance or elevated fasting blood glucose Risk Profile: No suppression of natural testosterone Not liver toxic Long-term users should monitor fasting glucose, A1C , and IGF1 levels MK677 increases GH and IGF1 levels but may reduce insulin sensitivity and increase appetite and edema at higher doses. Murphy et al., Growth Hormone & IGF Research CJC1295 (without DAC) Common Side Effects: Injection site irritation Water retention (mild) Headaches from elevated GH levels Vivid dreams or sleep disturbances (rare) Risk Profile: Does not suppress natural GH production Well tolerated in most users Elevated IGF1 over time may contribute to joint tightness or carpal tunnellike symptoms at high doses CJC1295-induced elevation in IGF1 may cause dose-related adverse effects such as arthralgia and fluid retention. Teichman et al., JCEM TB500 Common Side Effects: Injection site redness or inflammation Temporary fatigue or dizziness post-injection Mild headache or nausea (rare) Risk Profile: Low toxicity No known hormonal suppression Anecdotal reports suggest improved recovery with minimal downside Limited human data
G.LeeY.KimD
Serum levels of IGF-I and IGFBPs expression At the time of sacrifice (day 29 th ), 1416 hours after the last IGF-I injection, surprisingly serum levels of IGF-I did not increase in rats with testicular atrophy treated with IGF-I (AT+IGF) (CO: 2257 183 ng/ml
As illustrated in the volcano plot (Fig
